Researchers have made tremendous progress in cancer prevention and treatment over the past few decades. As a result, the death rates for many common cancers are declining in the U.S.1 Unfortunately, not everyone is benefitting from these breakthroughs.
In the field of radiation oncology there is currently tremendous excitement about the delivery of radiation at much higher dose rates than typically used clinically.
In health, the immune system plays a key role in protecting us not only from infectious disease, but also from the development of cancer; immune cells recognize and destroy harmful agents, whether pathogens or malignant cells.
Over the past year, we have witnessed the awesome power of American pharmaceutical and biotechnology companies.
In March 2010, as part of Affordable Care Act, Congress passed a well-conceived and critical legislative bill, the Biologic Pricing and Competition Innovation Act of 2009 (BPCIA)
Every person facing a cancer diagnosis deserves access to the best possible tests and treatments for their disease. It’s really that simple. Even better—it’s entirely feasible.
Becky Stephens is more than willing to go to great lengths for a miracle. With a diagnosis of stage 4 colon cancer and chemo treatments that weren’t working, she was desperate for hope—and found it in a clinical trial.
The development of more effective cancer treatment has yielded higher cure rates, longer survival, and a decrease in cancer recurrence. As of January 2019, the National Cancer Institute estimated that there were 16.9 million cancer survivors in the United States.
As cannabis (marijuana) legalization expands in the United States, its medical use is becoming more prevalent in patients with cancer. Despite high patient interest, large well-conducted clinical trials are limited and few oncologists feel they have sufficient training to make informed recommendations about cannabis.
A profound, difficult, seemingly impossible human journey begins with the words, “you have cancer.”
